Jeff E. Knight - Jul 26, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jul 26, 2022
Transactions value $
-$3,756
Form type
4
Date filed
7/29/2022, 04:26 PM
Previous filing
Mar 2, 2022
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $20.1K +1.15K +23.27% $17.44 6.1K May 20, 2022 Direct F1
transaction CRNX Common Stock Sale -$23.8K -1.15K -18.88% $20.70 4.95K Jul 26, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.7004 per share. The range of actual sales prices on the transaction date was $20.69 to $20.7016 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.